Targeted failure of the week. Post No 111. Krystexxa's pegylated disaster

Krystexxxxxxxxxxxa-hhhhkhkhkh. Well, it is not only targeted failure but a pegylated disaster:

From Wiki: Pegloticase (or Krystexxa) is a tetrameric peptide composed of four identical chains of about 300 amino acids each. Approximately nine of the 30 lysine residues in each chain are pegylated. These side chains consist of about 225 ethylene glycol units each.

And what happend?

Krystexxa, which treats chronic gout in adults who do not respond to conventional therapy, has had disappointing sales since its launch in September 2010.

Savient listed total assets of about $74 million and liabilities of $260 million as of June 30, court documents filed on Monday showed.

Shares of the company, which have fallen 47 percent this year, closed at 57 cents on Monday on the Nasdaq.